Euroopan unioni - slovakki - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastické činidlá - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacienti, ktorí majú nízky alebo veľmi nízke riziko opakovania by nemalo prijímať adjuvantná liečba. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. okrem novo diagnostikovaných chronickej fáze cml, nie sú tam žiadne kontrolovaných štúdií dokazuje, klinický prospech alebo zvýšené prežitie týchto ochorení.

Euroopan unioni - slovakki - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - nádory štítnej žľazy - antineoplastické činidlá - liečba dospelých pacientov s progresívnym, neresekovateľným lokálne pokročilým alebo metastatickým medulárnym karcinómom štítnej žľazy.

Euroopan unioni - slovakki - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastické činidlá - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck spol. s r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck spol. s r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck spol. s r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck spol. s r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ibsa slovakia s.r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ibsa slovakia s.r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ibsa slovakia s.r.o., slovensko - levotyroxín, sodná soľ - 56 - hormona (lieČiva s hormonÁlnou aktivitou)